Abstract
1,25-dihydroxyvitamin D3 (1,25(OH)2D3) and its analogues have been shown to inhibit proliferation of human cancer cells mediated by vitamin D receptor (VDR). The over-expression of 25-hydroxyvitamin D-24-hydroxylase (CYP24A1), an enzyme involved in the metabolism of 1,25(OH)2D3 and its analogues, is associated with poor prognosis of some human cancers. In this study, we employed real-time reverse transcription PCR to examine the expression of VDR and CYP24A1 mRNA in a cohort of human breast, lung, colon and ovary tumor samples. We found that CYP24A1 mRNA was significantly up-regulated in colon, ovary and lung tumors, but down-regulated in breast tumor relative to the analogous normal tissues. As a comparison, VDR mRNA was modestly down-regulated in colon, breast and lung tumors, but highly up-regulated in ovarian tumors. Treatment of two breast cancer cell lines, SW-620 and MCF-7, and one colon cancer cell line, HT-29, by 1,25(OH)2D3 for 48 h profoundly stimulated CYP24A1 mRNA expression (EC50=0.6, 0.8 and 29.5 nM in SW-620, HT-29 and MCF-7, respectively), but did not significantly affect VDR mRNA expression. Growth as assessed by DNA synthesis was modestly arrested by 1,25(OH)2D3 after 72 h of incubation, but was not altered after a 5-day incubation period. These data suggest that the VDR signaling pathway may be compromised via the modulation of CYP24A1 and VDR in human tumors.
Similar content being viewed by others
References
Brown AJ, Dusso AS, Slatopolsky E (2002) Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant 17:10–19
Wu-Wong JR, Tian J, Goltzman D (2004) Vitamin D analogs as therapeutic agents: a clinical study update. Curr Opin Investig Drugs 5:320–326
Carlberg C, Quack M, Herdick M, Bury Y, Polly P, Toell A (2001) Central role of VDR conformations for understanding selective actions of vitamin D(3) analogues. Steroids 66:213–221
Jones G, Strugnell SA, DeLuca HF (1998) Current understanding of the molecular actions of vitamin D. Physiol Rev 78:1193–1231
Banerjee P, Chatterjee M (2003) Antiproliferative role of vitamin D and its analogs—a brief overview. Mol Cell Biochem 253:247–254
Rao A, Coan A, Welsh JE, Barclay WW, Koumenis C, Cramer SD (2004) Vitamin D receptor and p21/WAF1 are targets of genistein and 1,25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res 64:2143–2147
Christensen GL, Jepsen JS, Fog CK, Christensen IJ, Lykkesfeldt AE (2004) Sequential versus combined treatment of human breast cancer cells with antiestrogens and the vitamin D analogue EB1089 and evaluation of predictive markers for vitamin D treatment. Breast Cancer Res Treat 85:53–63
Agadir A, Lazzaro G, Zheng Y, Zhang XK, Mehta R (1999) Resistance of HBL100 human breast epithelial cells to vitamin D action. Carcinogenesis 20:577–582
Humeniuk-Polaczek R, Marcinkowska E (2004) Impaired nuclear localization of vitamin D receptor in leukemia cells resistant to calcitriol-induced differentiation. J Steroid Biochem Mol Biol 88:361–366
Rustin GJ, Quinnell TG, Johnson J, Clarke H, Nelstrop AE, Bollag W (1996) Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer. Br J Cancer 74:1479–1481
Shabahang M, Buras RR, Davoodi F, Schumaker LM, Nauta RJ, Evans SR (1993) 1,25-Dihydroxyvitamin D3 receptor as a marker of human colon carcinoma cell line differentiation and growth inhibition. Cancer Res 53:3712–3718
Albertson DG, Ylstra B, Segraves R, Collins C, Dairkee SH, Kowbel D, Kuo WL, Gray JW, Pinkel D (2000) Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat Genet 25:144–146
Bortman P, Folgueira MA, Katayama ML, Snitcovsky IM, Brentani MM (2002) Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review. Braz J Med Biol Res 35:1–9
Mimori K, Tanaka Y, Yoshinaga K, Masuda T, Yamashita K, Okamoto M, Inoue H, Mori M (2004) Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol 15:236–241
Denizot F, Lang R (1986) Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Meth 89:271–277
Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ (2000) Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Clin Cancer Res 6:1833–1839
Saunders DE, Christensen C, Lawrence WD, Malviya VK, Malone JM, Williams JR, Deppe G (1992) Receptors for 1,25-dihydroxyvitamin D3 in gynecologic neoplasms. Gynecol Oncol 44:131–136
Saunders DE, Christensen C, Williams JR, Wappler NL, Lawrence WD, Malone JM, Malviya VK, Deppe G (1995) Inhibition of breast and ovarian carcinoma cell growth by 1,25-dihydroxyvitamin D3 combined with retinoic acid or dexamethasone. Anticancer Drugs 6:562–569
Banwell CM, Singh R, Stewart PM, Uskokovic MR, Campbell MJ (2003) Antiproliferative signalling by 1,25(OH)2D3 in prostate and breast cancer is suppressed by a mechanism involving histone deacetylation. Rec Results Cancer Res 164:83–98
Banwell CM, O’Neill LP, Uskokovic MR, Campbell MJ (2004) Targeting 1alpha,25-dihydroxyvitamin D3 antiproliferative insensitivity in breast cancer cells by co-treatment with histone deacetylation inhibitors. J Steroid Biochem Mol Biol 89–90:245–249
Krishnan AV, Peehl DM, Feldman D (2003) Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 88:363–371
Ly LH, Zhao XY, Holloway L, Feldman D (1999) Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140:2071–2076
Peehl DM, Seto E, Hsu JY, Feldman D (2002) Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. J Urol 168:1583–1588
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Anderson, M.G., Nakane, M., Ruan, X. et al. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother Pharmacol 57, 234–240 (2006). https://doi.org/10.1007/s00280-005-0059-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00280-005-0059-7